Anzeige
Mehr »
Freitag, 09.01.2026 - Börsentäglich über 12.000 News
Fundamental stark, Kurs zu niedrig - Chance beim Krebs-Impfstoff-Pionier!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
31 Leser
Artikel bewerten:
(0)

Basic Organics Announces Launch of Cardia 7'

COLUMBUS, Ohio, Feb. 16, 2012 /PRNewswire/ --February is heart-health month, yet one month seems inadequate, considering how prevalent cardiovascular disease is in this country. Heart disease is still the number one killer of adults, causing more than 900,000 deaths each year in the U.S. alone. That is why Basic Organics is glad to announce the launch of their new heart supplement, Cardia 7'.

Image:
http://www.ereleases.com/pic/2012-Cardia7.jpg

Dubbed "The Heartier Omega," Cardia 7 contains ultrapurified concentrations of Omega 7 (palmitoleic acid). Research has shown that palmitoleic acid, which is completely natural and derived from the monounsaturated (MUFA) family of fatty acids, can simultaneously: (1) increase HDL cholesterol ("good cholesterol"), (2) lower LDL cholesterol ("bad cholesterol"), and (3) lower triglycerides--without the flushing effects of niacin.

"It is well established that niacin helps reduce harmful cholesterol levels in the bloodstream," explains Jeffrey Green, Pharm.D., Director of Research at Tersus Pharmaceuticals. "Unfortunately, the use of niacin is often met with uncomfortable side effects of flushing, leading a significant number of consumers to discontinue its use. Cardia 7 is a great 'no-flush' alternative to niacin."

"The monounsaturated (MUFA) family of fatty acids have universally been shown to exhibit positive health benefits," affirms Dr. Green. "Whereas the saturated fatty acids are known to be the 'bad actors' in the Western diet. Cardia 7 has been clinically researched to target HDLs, which act like the garbage trucks of your bloodstream. HDL cholesterol transports bad cholesterol back to your liver, where it is metabolized and removed from your body. This is why HDL cholesterol is often referred to as 'good' or 'protective' cholesterol."

For this reason, in addition to being the fist ultrapurified form of palmitoleic acid on the market, Cardia 7 has been especially formulated to remove palmitic acid, a saturated fatty acid which is contained in many foods that are high in saturated fats, such as processed meats, cheeses, and dairy products. It is well documented that palmitic acid has been shown to have toxic effects on pancreatic beta cells, leading to a greater chance for insulin resistance and subsequent development of diabetes.

"Multiple research investigations have shown that palmitic acid increases beta cell death. Beta cells are the constituents within the pancreas that are responsible for insulin release. This could have far-reaching consequences for cardiovascular disease as well, since the epidemic involving the metabolic syndrome is comprised of the triad of insulin resistance, obesity and cardiovascular complications," continues Dr. Green. "All of these negative factors appear to be interconnected and act in concert in a negative manner in the body."

While there are current formulations of Omega 7 on the market, they should not be confused with Cardia 7. The concentration of palmitic acid from sea buckthorn sources contains upwards of 40% of palmitic acid, which actually exceeds the concentration in those preparations of the "good fatty acid," palmitoleic acid. The concentration of palmitic acid in Cardia 7 is limited to less than 2%.

"This is not just another new product launch. This is potentially an entirely new category," said Scott Johnson, President of Basic Organics. "Omega 7 has been shown to possess many of the health benefits consumers are actively seeking. Cardia 7 is a groundbreaking nutritional supplement that can help the people who are seeking to target optimal cholesterol levels to breathe a sigh of relief. Combining a healthy diet, regular exercise, and Cardia 7' capsules are great steps in efforts to maintain a healthy heart."

Cardia 7 is currently sold directly at http://www.cardia7.com, an e-commerce website that includes "The Heartier Blog," which contains more information on the science behind Omega 7, as well as information and resources to increase greater awareness of the link between health and nutrition. Cardia 7 is also available now at select GNC stores.

For more information, visit http://www.cardia7.com.

Cardia 7 was also featured in Muscle & Body Magazine in February 2012: "Stopping the 'Silent Killer,' Omega 7 (palmitoleic acid) strengthens the most important muscle in your body."

Cardia 7 is distributed by Basic Organics in Columbus, Ohio, a leader in the dietary and nutritional supplement business. Cardia 7 was developed and manufactured by Tersus Pharmaceuticals in Cleveland, Ohio. In early 2010, Tersus Pharmaceuticals was a recipient of Therapeutic Discovery Grant to Support Groundbreaking Biomedical Research.

Media Contact:
Les Proctor
Nicheworks
216-452-0049

This press release was issued through eReleases(R). For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.

SOURCE Basic Organics

© 2012 PR Newswire
Renditeturbo 2026 - 5 Aktien mit Potenzial
2025 neigt sich dem Ende zu, ohne klassische Jahresendrallye, aber mit einem DAX, der viele Kritiker Lügen gestraft hat. Über 21 Prozent Kursplus seit Jahresbeginn, stärker als der US-Markt. Wer hätte das noch vor Monaten erwartet?

Genau solche Entwicklungen machen den Reiz der Börse aus. Denn auch 2026 dürfte wieder alles anders kommen als gedacht. Während viele Analysten weiter steigende Kurse erwarten, rückt eine zentrale Frage in den Fokus: Wo entstehen im kommenden Jahr echte Überraschungen, und wie kann man davon profitieren?

Unser aktueller Spezialreport beleuchtet fünf Entwicklungen, mit denen kaum jemand rechnet, die aber enormes Renditepotenzial bergen. Vom Comeback der Ölwerte über unterschätzte Plattform-Aktien bis hin zur möglichen Wachablösung im KI-Sektor: Wer 2026 überdurchschnittlich abschneiden will, muss antizyklisch denken und frühzeitig Position beziehen.

Im kostenlosen Report stellen wir 5 Aktien vor, die 2026 im Zentrum solcher Wendepunkte stehen könnten. Solide bewertet, gut positioniert und mit überraschend starkem Momentum.

Jetzt kostenlos herunterladen! Bevor andere erkennen, wo die Chancen wirklich liegen!

Dieses exklusive PDF ist nur für kurze Zeit verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.